Altcoins Surge with Gaming, AI, Memecoins in the Lead-Is the Crypto Boom Back?

by

Well, well, well-what a surprise! It was the gaming sector that stole the show with some of the most delightful upward movements of the day. Immutable (IMX), Render (RNDR), and Virtuals Protocol (VIRTUAL) were the frontrunners, each making a delicious leap of over 11%, 13%, and 16%, respectively. It seems the gaming ecosystem is thriving on an abundance of developer activity and increasing demand. It was all rather thrilling, as platforms saw rising interactions and anticipation of some network-level improvements. You could almost hear the virtual applause. Beam and Portal, of course, were not about to miss out on the fun, basking in the glow of ecosystem growth.

Hedge Funds Bet Big on HCI – Is This a Wisdom or a Wager?

by

Alden’s new position inHCI Group (yes, they’re just having fun with acronyms these days) amounts to 62,940 shares, valued at $12.08 million. For context, that’s roughly the cost of buying out a small art collective-or, if you prefer, the equivalent of 7.06% of Alden’s 13F reportable assets. The fund now holds just 13 stocks total. And HCI? It’s their sixth-largest bet. I tip my hat. They’ve got taste, if not also a slight obsessions with alphabet soup ticker codes.

Gensler Declares Bitcoin the King, Calls Other Cryptos “Risky Nonsense” 🍿

by

But hold onto your top hat, because Gensler didn’t stop there! He singled out Bitcoin, old sport, as the one crypto that’s not entirely up the creek without a paddle. According to him, it’s more like a commodity, you see, and not just some digital doodad. 🎩 Bitcoin, he says, stands alone in the legitimacy stakes, while the rest of the crypto circus is a high-wire act without a net. 🤡

Remitly’s 16% Plunge: A Value Investor’s View 😊

by

Remitly’s story is a bold one: disrupting Western Union, strutting into the fintech arena with all the swagger of a startup that thinks money doesn’t matter. But here we are, staring at a stock price that’s more “pathetic” than “perseverance.” Classic market theater: praise the chorus of growth, then boo at the faintest hint of maturity.

A $68M Signal: General Atlantic’s Bet on Pharvaris

by

The SEC’s November 13, 2025, report reveals a subtle crescendo: General Atlantic’s stake in Pharvaris swelled to 8,031,252 shares, a figure that glows like a lantern in the twilight of the biotech sector. As of September 30, 2025, this portfolio piece was valued at $200.38 million-a testament to the company’s quiet promise.